title: α-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid.
abstract: OBJECTIVE
  To investigate the effects of α-tocopherol on pancreatic fibrosis and survival in rats with experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid (TNBS).
  
  
  METHODS
  Chronic pancreatitis was induced in male Sprague-Dawley rats by infusion of TNBS into the pancreatic duct. α-Tocopherol (300, 600 or 900 mg/kg) was orally administered to rats with experimental pancreatitis (treatment group) daily for 4 weeks. The relative pancreatic weight, pancreatic pseudocyst and death rate were observed. Paraffin-embedded tissue samples were sliced, stained by hematoxylin-eosin and histopathologically examined.
  
  
  RESULTS
  α-Tocopherol administration significantly ameliorated the pancreatic weight loss induced by TNBS in chronic pancreatitis rats compared to the control group. There were pancreatic pseudocysts in 69% of the α-tocopherol group, and in 100% of the control group. α-Tocopherol administration led to a significant increase of the survival rate. The histopathologic scores were higher in the control group than in the α-tocopherol group. Subgroup analysis of histopathologic scores revealed that a high dose of α-tocopherol results in less pancreatic injuries.
  
  
  CONCLUSIONS
  α-Tocopherol treatment elevates survival rate, extenuates fibrosis and increases relative pancreatic weight in the chronic pancreatitis model. α-Tocopherol therapy in chronic pancreatitis is now required to confirm these findings and establish the role of this treatment in the management of this disabling condition. and IAP.
authors.affiliation: Department of Geratology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: X C
authors.initials: XC
authors.lastname: Li
authors.forename: X L
authors.initials: XL
authors.lastname: Lu
authors.forename: H H
authors.initials: HH
authors.lastname: Chen
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D018572:Disease-Free Survival; D005355:Fibrosis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control; D053208:Kaplan-Meier Estimate; D008136:Longevity / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects* / Q000473:pathology; D010192:Pancreatic Pseudocyst / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control; D050500:Pancreatitis, Chronic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity; D024502:alpha-Tocopherol / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D014302:Trinitrobenzenesulfonic Acid; D024502:alpha-Tocopherol